News

Myriad has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to

Under the terms of the OTC license agreement, Schering-Plough is responsible for the development, manufacturing and commercialization of OTC products using Santarus’ proton pump inhibitor (PPI) technology with

The results, which have been published Annals of Neurology, are from two studies over two years designed to asses the relationship between disease activity and health-related quality-of-life (HRQoL)

“In addition to demonstrating that Neuvenge was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other

The original five-year contract was signed in August 2002, and under that contract Cangene developed and delivered vaccinia immune globulin intravenous (VIG) product to the US strategic national

The company’s two previously announced Phase II trials are studying primary brain cancer and melanoma that has spread to the brain. This third Phase II trial is designed

Carrington says the toxicology studies are a critical step during the vaccine development and will assess the vaccine safety in animals. Pending successful results of the toxicology studies

The clinical trial is designed to evaluate the effectiveness and safety of Alinia tablets administered in combination with Pegasys and Copegus in 60 patients with chronic hepatitis C

Under the terms of the agreement, Millipore will have exclusive worldwide rights to market and sell Novo Nordisk’s recombinant human insulin, branded by Millipore as Incelligent SG and